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osting by EAbstract Background: Pityriasis versicolor is a superﬁcial fungal infection of the skin. Multiple
modalities of therapy have been used including both topical and systemic agents, such as imida-
zoles, triazoles and allylamines.
Objective: To evaluate the effectiveness of topical 1% diclofenac gel in the treatment of pityriasis
versicolor in comparison with topical clotrimazole cream and aqua rosa cream as a placebo control.
Patients and methods: This is a single-blinded, comparative therapeutic trial of topical 1% diclofe-
nac gel in the treatment of pityriasis versicolor in comparison with topical 1% clotrimazole
cream and aqua rosa cream as a placebo control group was conducted at the Department of
Dermatology – Baghdad Teaching Hospital during November 2006–November 2008.
This study included 75 patients (39 males and 36 females). They were divided randomly into three
groups, each containing 25 patients. Group A patients treated with diclofenac gel: include 15 (60%)
males and 10 (40%) females. Their ages ranged from 15 to 44 (23.72 ± 6.52) years, while the
duration of the disease ranged from 1 to 24 (4.28 ± 5.79) months. Group B patients treated withntiﬁc Council of Dermatology
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4 Baghdad, Iraq. Tel.: +964
k (K.E. Sharquie).
y. Production and hosting by
Saud University.
lsevier
20 K.E. Sharquie et al.clotrimazole cream: composed of 13 (52%) males and 12 (48%) females, their ages ranged from
15 to 38 (22.56 ± 5.09) years, and the duration of the disease ranged from 1 to 18 (3.76 ±
3.98) months. Group C patients treated with aqua rosa cream: contain 11 (44%) males and 14
(56%) females, their ages ranged from 16 to 33 (23.68 ± 4.98) years and the duration of the disease
ranged from 1 to 18 (3.26 ± 3.53) months. Detailed history, close clinical examination, skin scrap-
ing test and Wood’s light examination were done for all patients. Patients with immune suppression
conditions or who received treatment during the last 2 months before the beginning of the study
were excluded. Every patient was instructed to apply the drug twice daily for 1-month and to be
seen every 2 weeks during the treatment and the follow up which is another 1-month. All patients
were assessed clinically; skin scraping test and Wood’s light examination were done at each visit.
Results: The result of this study revealed that at the end of 4 weeks: in Group A 14 (56%) patients
had complete improvement (P value = 0.00004), while in Group B 23 (92%) patients had complete
improvement (P value <0.00000001) and no one achieved complete improvement in Group C. Mild
side effects were recorded as itching in few patients, which do not need to discontinue the therapy.
Conclusion: Diclofenac gel proved to be an effective, new topical treatment for pityriasis versicolor
infections, and it is safe with no important side effects and well tolerated by the patients, but in the
present concentration (1%) it cannot compete with other much superior topical drugs.
ª 2010 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Pityriasis versicolor is a mild chronic infection of the skin
caused by Malassezia yeast, and characterized by discrete or
concrescent, scaly, discolored or depigmented areas mainly
on the upper trunk (Hay and Moore, 2004).
Several modalities have been used in the treatment of pity-
riasis versicolor with both topical like imadzoles, selenium
sulphide shampoos and lotions, ciclopirox olamine, zinc pyri-
thione shampoos, sulphur preparations, salicylic acid prepara-
tions, propylene glycol lotions, tretinoin cream, terbinaﬁne
solution, benzyl peroxide, zinc sulphate lotion and lactic acid
lotion, and systemic antifungal like itraconazole, ﬂuconazole
and ketoconazole with different mechanisms of their action
(Gupta et al., 2002; Sharquie, 1991; Sharquie et al., 2008,
2009; Al-Tereihi, 2007).
Topical diclofenac gel is a non-steroidal anti-inﬂammatory
drug. In dermatology 3% diclofenac gel is used for the topical
treatment of actinic keratosis (Rivers et al., 2002; Kose et al.,
2008). Diclofenac gel also used in treatment of genital poroker-
atosis (Kluger et al., 2007), rosacea (Weiss et al., 2008) and alo-
pecia areata (Sharqie et al., 2006).
The aim of the present work is to evaluate its effectiveness in
the treatment of pityriasis versicolor in comparison to clotrim-
azole cream and aqua rosa cream as a placebo control group.
2. Patients and methods
This is a single-blinded, comparative therapeutic study of 1%
diclofenac gel in comparison to 1% clotrimazole cream and
aqua rosa cream as a placebo control group in the treatment
of pityriasis versicolor. The study was carried out in the
Department of Dermatology and Venereology – Baghdad
Teaching Hospital from November 2006 to November 2008.
Seventy-ﬁve patients with pityriasis versicolor were included
in this study. Full history was taken from each patient regard-
ing: age, sex, duration of disease, family history, seasonal var-
iation, previous personal history of the disease and any
previous treatment used for it.
Examination of the patients and assessment of the disease
were performed by:1. Clinical examination of the lesion, reporting the site, size,
color, presence of the scales and erythema.
2. Wood’s light examination: was to conﬁrm the diagnosis
through showing yellow ﬂuorescence of the lesions, this test
was positive, also to determine the site, extent of the lesions.
3. Skin scraping test by dissolving the scales in 10% KOH
solution, the test is considered positive when it reveals short
stubby hyphae and yeast forms.
All patients were photographed by a digital camera as a
baseline and then every 2 weeks, in the same place with ﬁxed
illumination and distance by using a digital camera (Sony:
Cyber shoot with resolution 7 mega pixels).
From each patient, formal consent was taken before the
start of therapy, after full explanation about the nature of
the disease, course, methods of treatment, follow up and prog-
nosis. Also, the ethical approval was performed by the scien-
tiﬁc committee of the Scientiﬁc Council of Dermatology and
Venereology – Iraqi Board for Medical Specializations.
The patients were divided randomly into three groups each
contains 25 patients:
GroupApatients treatedwith diclofenac gel:Patients included
in this group were 15 (60%) males and 10 (40%) females.
Group B patients treated with clotrimazole cream: Cases
involved in this group were 13 (52%) males and 12 (48%)
females.
Group C patients treated with aqua rosa cream: Patients
composed in this group were 11 (44%) males and 14
(56%) females.
The treatment was applied twice daily as a thin coating to
the entire lesion and to normal skin around the lesions.
Re-evaluation was done for each patient by performing
physical examination, skin scraping test and Wood’s light
examination every 2 weeks during the month of therapy and
for the second month of follow up to report clinical and myco-
logical responses and any signs and symptoms of local and sys-
temic side effects.
Preparations: Diclofenac gel (Voltaren Emulgel). Each
100 g of the gel contains the active substance diclofenac
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well as propylene glycol and ﬂavoring agents. The base of Vol-
taren Emulgel is a fatty emulsion in an aqueous gel to which
isopropanol and propylene glycol have been added. Emulgel
is 20 g tubes. It is manufactured by: NOVARTIS PHARMA,
Switzerland.
Clotrimazole cream is obtained from MEDICO LABS,
Syria 20 g tubes each 1 g contains 10 mg of clotrimazole.
The clinical response score was performed depending on
Sharquie et al. score (Sharquie et al., 2008; Al-Tereihi, 2007):
No response: There is no response on clinical examination
and on skin scraping test examination.
Partial response: There is some clinical improvement
(decrease in scales) or skin scraping test change to negative
results.
Complete response: Both clinical and skin scraping test
examinations indicate resolution.
Improvement of pigmentory changes was not a criterion for
response to treatment; this is because return of normal pigmen-
tation may take several weeks after the clearance of pityriasis
versicolor.
Statistical analysis was done by EP16 system, v2 matching
between the groups. P value of less than 0.05 was considered
signiﬁcant.
3. Results
In general for all patients, the diagnosis proved was by
clinical, mycological and Wood’s light examinations. This
study included 75 patients {39 (52%) males and 36 (48%)
females}.
Group A: The clinical response in patients treated with top-
ical diclofenac gel.
After 2 weeks of treatment, 4 (16%) patients showed com-
plete improvement (clinically and mycologically), while the re-
sponse after 4 weeks of treatment was 14 (56%) patients
with complete improvement (Yates corrected v2 = 16.77,
P value = 0.00004) (Fig. 1).Figure 1 (A) Before treatment by diclofenac gel. (The difference in clinical response in patients between
2 weeks and 4 weeks was signiﬁcant (Yates corrected v2 =
7.03, P value = 0.008).
Group B: The clinical response in patients who were treated
with topical clotrimazole cream after 2 weeks of treatment
was 14 (56%) patients with complete improvement, while the
result after 4 weeks of treatment was 23 (92%) patients
with complete healing (Yates corrected v2 = 38.9, P value
<0.00000001). The difference in clinical response in patients
between 2 weeks and 4 weeks was signiﬁcant (Yates corrected
v2 = 6.65, P value = 0.009) (Fig. 2).
Group C: The clinical response in patients who were treated
with topical aqua rosa cream, no patients showed either partial
or complete improvement after 2 or 4 weeks of treatment.
In comparison between groups A and B there was signiﬁ-
cant difference at 2 weeks (Yates corrected v2 = 7.03,
P value = 0.008) and at 4 weeks (Yates corrected v2 = 6.65,
P value = 0.009).
In comparison between groups A and C there is no signif-
icant difference at 2 weeks (Yates corrected v2 = 2.45, P
value = 0.1) but signiﬁcant difference at 4 weeks (Yates cor-
rected v2 = 16.77, P value = 0.00004) (Tables 1 and 2).
4. Discussion
Pityriasis versicolor is a common yeast infection of the skin
encountered in daily practice affecting adult people with unac-
cepted cosmetic effects pityriasis versicolor, which recurs fre-
quently despite adequate initial therapy (Hay and Moore,
2004).
There are many therapeutic agents effective for treatment
of pityriasis versicolor who are either topical like clotrimazole,
ketoconazole, oxiconazole, terbinaﬁne, selenium sulphide, tret-
inoin, ciclopirox olamine, zinc sulphate and lactic acid or sys-
temic including itraconazole, ﬂuconazole and ketoconazole.
Despite these many therapies there is no standard therapy with
complete cure rate (Gupta et al., 2002; Sharquie, 1991; Shar-
quie et al., 2008, 2009; Al-Tereihi, 2007).
Topical diclofenac gel is a non-steroidal anti-inﬂammatory
drug. In dermatology 3% diclofenac gel is used for the topicalB) After 4 weeks treatment with diclofenac gel.
Table 1 Clinical response among patients.
At 2 weeks At 4 weeks
Group No response Partial response Complete response No response Partial response Complete response
n % n % n % n % n % n %
A 2 8 19 76 4 16 1 4 10 40 14 56
B 0 0 11 44 14 56 0 0 2 8 23 92
C 6 24 19 92 0 0 5 20 20 80 0 0
Table 2 Comparison of skin scraping test among patients
during treatment.
Group At 2 weeks (+ve) At 4 weeks (+ve)
n % n %
A 14 56 7 28
B 9 36 2 8
C 22 88 20 80
Figure 2 (A) Before treatment with clotrimazole cream. (B) After 4 weeks treatment with clotrimazole.
22 K.E. Sharquie et al.treatment of actinic keratosis (Rivers et al., 2002; Kose et al.,
2008). Diclofenac gel also used in treatment of genital poroker-
atosis (Kluger et al., 2007), rosacea (Weiss et al., 2008) and alo-
pecia areata (Sharqie et al., 2006).
The results of the present work showed that both diclofenac
gel and clotrimazole cream were effective in clearing the lesions
of pityriasis versicolor. At 2 weeks of therapy, diclofenac gel
cleared 16% of the patients while clotrimazole cream cleared
56% of patients. After 4 weeks of therapy, diclofenac gel
cleared 56% of patients while clotrimazole cream was more
effective which cleared 92% of patients.
Diclofenac gel appeared to be more effective at 4 weeks
than at 2 weeks (P value = 0.008). Clotrimazole cream also
appeared to be more effective at 4th weeks than at 2nd weeks
(P value = 0.009).
Diclofenac gel in comparison to placebo appeared to be
highly effective at 4th weeks of therapy (P value = 0.00004).
In previous Iraqi studies: Sharquie showed that tretinoin
cream is highly effective in the treatment of pityriasis versi-color with cure rate 100% after 2 weeks of therapy but with
noticeable side effects like erythema and itching (Sharquie,
1991). Sharquie et al. showed that zinc sulphate in 15% topical
solution is highly effective treatment of pityriasis versicolor
with cure rate 100% at 3 weeks therapy (Sharquie et al., 2008).
Also, Al-Tereihi showed that zinc sulphate in 10% topical
solution is an effective treatment of pityriasis versicolor with
cure rate 68% after 4 weeks of therapy (Al-Tereihi, 2007).
Sharquie et al. showed that 10% lactic acid solution is
highly effective in treatment of pityriasis versicolor with cure
rate 100% after 4 weeks of therapy (Sharquie et al., 2009).
While; clotrimazole, as an imidazole antifungal agent exerts
its activity by altering the cell membrane permeability by
inhibiting the 14-alpha-demethylation of lanosterol which
inhibits ergosterol necessary for normal cell membrane perme-
ability. Diclofenac may act via an effect on matrix metallopro-
teinases which have been elevated with diclofenac. Over
expression of metalloproteinases would have keratolytic action
capable of degrading collagen and epidermal cytoskeletal ele-
ments (Kose et al., 2008).
The residual post-inﬂammatory hypopigmentation
occurred in both drugs similarly. To the best of our knowl-
edge, this is the ﬁrst work showing the effectiveness of topical
diclofenac gel in the treatment of pityriasis versicolor and
apart from minimal irritation in few cases it lacks any other
side effects in contrast to many other topical therapies like tret-
inoin cream and sulphur which are associated with marked
irritation, but still it was much less effective when compared
with clotrimazole, zinc sulphate, lactic acid and selenium
sulphide.
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In conclusion, diclofenac gel seems to be effective, cosmetically
accepted and safe treatment for pityriasis versicolor with
acceptable cure rate but in the present concentration (1%) it
cannot compete with other much superior topical drugs. Fur-
ther studies are highly recommended to have more conﬁrma-
tion of the present ﬁndings.
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